MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET–SOCS1–MMP9 signaling axis

被引:0
|
作者
Qing Chen
Dan Yin
Yong Zhang
Lei Yu
Xue-Dong Li
Zheng-Jun Zhou
Shao-Lai Zhou
Dong-Mei Gao
Jie Hu
Cheng Jin
Zheng Wang
Ying-Hong Shi
Ya Cao
Jia Fan
Zhi Dai
Jian Zhou
机构
[1] Key Laboratory of Carcinogenesis and Cancer Invasion,
[2] Liver Cancer Institute,undefined
[3] Zhongshan Hospital,undefined
[4] Fudan University,undefined
[5] Ministry of Education,undefined
[6] Institute of Biomedical Sciences,undefined
[7] Fudan University,undefined
[8] Key Laboratory of Carcinogenesis and Cancer Invasion,undefined
[9] Cancer Research Institute,undefined
[10] Central South University,undefined
[11] Ministry of Education,undefined
[12] State Key Laboratory of Genetic Engineering,undefined
[13] Fudan University,undefined
来源
Cell Death & Disease | 2017年 / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Ten eleven translocation (TET) enzymes convert 5-methylcytosine (5-mC) to 5-hydroxy-methylcytosine (5-hmC) and have crucial roles in biological and pathological processes by mediating DNA demethylation, however, the functional role of this epigenetic mark and the related enzymes in hepatocellular carcinoma (HCC) progression remains unknown. Here, we demonstrated that TET-family enzymes downregulation was one likely mechanism underlying 5-hmC loss in HCC. We found that miR-29a overexpression increased DNA methylation of suppressor of cytokine signaling 1 (SOCS1) promoter was associated with HCC metastasis in vitro and in vivo. Furthermore, miR-29a silenced anti-metastatic SOCS1 through direct TET-family targeting, resulting in SOCS1 promoter demethylation inhibition. Chromatin immunoprecipitation analyses confirmed that TET1 regulated SOCS1 expression through binding to the promoter region of SOCS1. Finally, miR-29a overexpression correlated with poor clinical outcomes and TET–SOCS1–matrix metalloproteinase (MMP) 9 axis silencing in HCC patients. In conclusion, our findings demonstrate that 5-hmC loss is an epigenetic hallmark of HCC, and miR-29a is an important epigenetic modifier, promoting HCC metastasis through TET–SOCS1–MMP9 axis silencing. The results offer a new strategy for epigenetic cancer therapy.
引用
收藏
页码:e2906 / e2906
相关论文
共 38 条
  • [1] MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis
    Chen, Qing
    Yin, Dan
    Zhang, Yong
    Yu, Lei
    Li, Xue-Dong
    Zhou, Zheng-Jun
    Zhou, Shao-Lai
    Gao, Dong-Mei
    Hu, Jie
    Jin, Cheng
    Wang, Zheng
    Shi, Ying-Hong
    Cao, Ya
    Fan, Jia
    Dai, Zhi
    Zhou, Jian
    CELL DEATH & DISEASE, 2017, 8 : e2906 - e2906
  • [2] MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis (vol 15 , 828 , 2024)
    Chen, Qing
    Yin, Dan
    Zhang, Yong
    Yu, Lei
    Li, Xue-Dong
    Zhou, Zheng-Jun
    Zhou, Shao-Lai
    Gao, Dong-Mei
    Hu, Jie
    Jin, Cheng
    Wang, Zheng
    Shi, Ying-Hong
    Cao, Ya
    Fan, Jia
    Dai, Zhi
    Zhou, Jian
    CELL DEATH & DISEASE, 2024, 15 (11):
  • [3] Decrease of 5-Hydroxymethylcytosine Is Associated with Progression of Hepatocellular Carcinoma through Downregulation of TET1
    Liu, Chungang
    Liu, Limei
    Chen, Xuejiao
    Shen, Junjie
    Shan, Juanjuan
    Xu, Yanmin
    Yang, Zhi
    Wu, Lin
    Xia, Feng
    Bie, Ping
    Cui, Youhong
    Bian, Xiu-wu
    Qian, Cheng
    PLOS ONE, 2013, 8 (05):
  • [4] Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis
    Guo, Xiao-Jun
    Huang, Xiao-Yong
    Yang, Xuan
    Lu, Jia-Cheng
    Wei, Chuan-Yuan
    Gao, Chao
    Pei, Yan-Zi
    Chen, Yi
    Sun, Qi-Man
    Cai, Jia-Bin
    Zhou, Jian
    Fan, Jia
    Ke, Ai-Wu
    Shi, Yujiang G.
    Shen, Ying-Hao
    Zhang, Peng-Fei
    Shi, Guo-Ming
    Yang, Guo-Huan
    CELL DEATH & DISEASE, 2023, 14 (02)
  • [5] Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis
    Xiao-Jun Guo
    Xiao-Yong Huang
    Xuan Yang
    Jia-Cheng Lu
    Chuan-Yuan Wei
    Chao Gao
    Yan-Zi Pei
    Yi Chen
    Qi-Man Sun
    Jia-Bin Cai
    Jian Zhou
    Jia Fan
    Ai-Wu Ke
    Yujiang G. Shi
    Ying-Hao Shen
    Peng-Fei Zhang
    Guo-Ming Shi
    Guo-Huan Yang
    Cell Death & Disease, 14
  • [6] Loss of Barx1 promotes hepatocellular carcinoma metastasis through up-regulating MGAT5 and MMP9 expression and indicates poor prognosis
    Wang, Guodong
    Liu, Jian
    Cai, Yi
    Chen, Jie
    Xie, Wenbing
    Kong, Xiangqian
    Huang, Wenjie
    Guo, Hao
    Zhao, Xiaodi
    Lu, Yuanyuan
    Niu, Lu
    Li, Xiaowei
    Zhang, Haijia
    Lei, Chao
    Lei, Zhijie
    Yin, Jipeng
    Hu, Hao
    Yu, Fan
    Nie, Yongzhan
    Xia, Limin
    Wu, Kaichun
    ONCOTARGET, 2017, 8 (42) : 71867 - 71880
  • [7] Epithelial-Mesenchymal Transformation Promotes the Progression of Hepatocellular Carcinoma through NF-κB/MMP9 Axis
    Li, Jinsen
    Cai, Qingbin
    Wang, Ziyue
    Wang, Liangshi
    Yang, Guangrun
    Zhang, Zhilong
    Ge, Na
    Hu, Shunxin
    Bai, Tian
    DISCOVERY MEDICINE, 2024, 36 (183) : 666 - 677
  • [8] RETRACTED: IFITM3 promotes hepatocellular carcinoma invasion and metastasis by regulating MMP9 through p38/MAPK signaling (Retracted Article)
    Min, Jiaqi
    Feng, Qian
    Liao, Wenjun
    Liang, Yiming
    Gong, Chengwu
    Li, Enliang
    He, Wenfeng
    Yuan, Rongfa
    Wu, Linquan
    FEBS OPEN BIO, 2018, 8 (08): : 1299 - 1311
  • [9] Loss of CDH1 promotes the metastasis of hypopharyngeal squamous cell carcinoma through the STAT3-MMP-9 signaling pathway
    Mu, Lan
    Liu, Xianfang
    Liu, Xiuxin
    Sa, Na
    Zhou, Shengli
    Lv, Zhenghua
    Xu, Wei
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (04) : 1476 - +
  • [10] Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis
    Liu, Feng
    Zhang, Hui
    Xie, Fei
    Tao, Dan
    Xiao, Xingyuan
    Huang, Chao
    Wang, Miao
    Gu, Chaohui
    Zhang, Xiaoping
    Jiang, Guosong
    ONCOGENE, 2020, 39 (08) : 1696 - 1709